STOCK TITAN

GRI Bio (GRI) SEC Filings, Aug 13-27, 2025

GRI NASDAQ

GRI Bio filings document a clinical-stage biotechnology issuer developing Natural Killer T cell modulators and the public-company events tied to that business. The filings include 8-K disclosures covering GRI-0621 clinical trial updates in idiopathic pulmonary fibrosis, financial-result releases and press-release exhibits furnished under results of operations and other-events items.

The filing record also details capital structure and governance matters, including at-the-market common stock offering agreements and prospectus supplements, legal opinions for share issuance, certificate amendments for a reverse stock split, Nasdaq Capital Market compliance notices, special meeting voting results and adjustments affecting common stock, warrants, convertible securities and equity incentive plans.

Rhea-AI Summary

Vipin Chaturvedi, Chief Scientific Officer of GRI Bio, Inc. (GRI), reported receipt of a stock option award dated 08/26/2025 covering 11,854 options to purchase common stock at an exercise price of $1.41 per share. Following the reported transaction, he beneficially owns 11,854 options directly. The grant vests in two parts: 7,424 options vested in full on the grant date, while 4,430 options will vest in 12 substantially equal quarterly installments and become fully vested on the third anniversary of the grant. The option expiration date is 08/26/2035. The filing was signed by an attorney-in-fact on behalf of the reporting person.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
insider
-
Rhea-AI Summary

Camilla V. Simpson, a director of GRI Bio, acquired a stock option covering 5,994 shares of the issuer's common stock with an exercise price of $1.41. The option grant is exercisable beginning 08/26/2025 and expires 08/26/2035. Of the 5,994 underlying shares, 4,044 vested immediately and 1,950 vest in four substantially equal quarterly installments so the option is fully vested on the first anniversary of the grant. Following the reported transaction, Ms. Simpson beneficially owns 5,994 shares and holds them in a direct ownership form. The Form 4 was submitted by one reporting person and signed by an attorney-in-fact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
insider
-
Rhea-AI Summary

GRI Bio, Inc. reported a Form 4 showing that Chief Financial Officer Leanne Kelly was granted a stock option on 08/26/2025 to purchase 11,854 shares of common stock at an exercise price of $1.41 per share. The option becomes exercisable immediately for 7,424 shares while the remaining 4,430 shares vest in 12 substantially equal quarterly installments, fully vesting on the third anniversary of the grant. The option expires on 08/26/2035. Following the transaction, Ms. Kelly beneficially owns 11,854 options directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
insider
Rhea-AI Summary

GRI Bio, Inc. filed a current report to make a new corporate presentation available to the market. The company is furnishing, rather than filing, this information under Regulation FD, which means the materials are provided for informational purposes and are not subject to certain liability provisions of the Exchange Act. The 8-K identifies the presentation as Exhibit 99.1, titled "GRI Bio, Inc. Corporate Presentation" and dated August 20, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
current report
-
Rhea-AI Summary

GRI Bio, Inc. director Camilla V. Simpson was granted a stock option on 08/13/2025 to buy 4,527 shares of common stock at an exercise price of $1.30 per share. The option appears in Table II as a derivative security with an expiration date of 08/13/2035. The filing states the option vests in four equal quarterly installments and is fully vested on the first anniversary of the grant date. The reporting person is shown as a director and the Form 4 was signed by an attorney-in-fact on 08/14/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
insider
-
Rhea-AI Summary

GRI Bio, Inc. director David Charles Baker was granted a stock option on 08/13/2025 to buy 4,527 shares of common stock at an exercise price of $1.30 per share. The option is exercisable with a vesting schedule of four equal quarterly installments and becomes fully vested on the first anniversary of the grant. The option expires on 08/13/2035. Following the grant, Mr. Baker beneficially owns 4,527 derivative shares on a direct basis. The Form 4 was signed by an attorney-in-fact, Leanne Kelly, on 08/14/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
insider
Rhea-AI Summary

Roelof Rongen, a director of GRI Bio, Inc. (GRI), was granted a stock option to buy 4,527 shares of common stock at an exercise price of $1.30 per share on 08/13/2025. The option vests in four equal quarterly installments and is fully vested on the first anniversary of the grant date, with an exercise/expiration schedule showing exercisability beginning 08/13/2025 and an expiration date of 08/13/2035. Following the grant, Mr. Rongen directly beneficially owns 4,527 underlying shares/options. The Form 4 was filed as a single reporting person filing and signed by an attorney-in-fact on 08/14/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
insider
-
Rhea-AI Summary

GRI Bio, Inc. director David Leslie Szekeres received a stock option grant on 08/13/2025 to purchase 7,545 shares of common stock. The Form 4 shows the derivative award is a stock option with a stated $1.30 conversion/exercise price and an expiration date of 08/13/2035. The option was reported as acquired on 08/13/2025 and is held directly. The award vests in four equal quarterly installments and is fully vested on the first anniversary of the grant date, per the filing. The Form 4 was signed by an attorney-in-fact on 08/14/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
insider
-
Rhea-AI Summary

GRI Bio is a clinical-stage biopharmaceutical company advancing oral iNKT/dNKT modulators. The company reported a net loss of $2.89 million for the quarter and $5.94 million for the six months ended June 30, 2025, driven by higher research and development spending on GRI-0621 ($1.88 million in Q2; $3.52 million six months) and ongoing company overhead.

Cash and cash equivalents were $5.12 million at period end; management forecasts this funding will support operations into the fourth quarter of 2025 but discloses substantial doubt about going concern without additional financing. Clinical progress includes completion of Phase 2a enrollment in July 2025, an Independent Data Monitoring Committee review reporting no safety concerns for early cohorts, and topline biomarker results expected in Q3 2025. Recent financings include an April 2025 offering (net $4.02 million) and ATM sales (net $4.29 million through June 30, 2025). The company disclosed a material weakness in internal controls.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.77%
Tags
quarterly report
Rhea-AI Summary

GRI Bio, Inc. filed a Form S-8 to register an additional 400,000 shares of common stock reserved for issuance under its Amended and Restated 2018 Equity Incentive Plan. The filing incorporates prior Form S-8 registrations by reference and includes the amended plan and related award agreement forms as exhibits. The registration increases the pool available for employee stock awards but does not disclose total shares outstanding or quantify potential dilution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.77%
Tags
registration

FAQ

How many GRI Bio (GRI) SEC filings are available on StockTitan?

StockTitan tracks 65 SEC filings for GRI Bio (GRI), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for GRI Bio (GRI)?

The most recent SEC filing for GRI Bio (GRI) was filed on November 13, 2026.